These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34254347)

  • 41. Deep historical borrowing framework to prospectively and simultaneously synthesize control information in confirmatory clinical trials with multiple endpoints.
    Zhan T; Zhou Y; Geng Z; Gu Y; Kang J; Wang L; Huang X; Slate EH
    J Biopharm Stat; 2022 Jan; 32(1):90-106. PubMed ID: 34632951
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Determination of the optimal sample size for a clinical trial accounting for the population size.
    Stallard N; Miller F; Day S; Hee SW; Madan J; Zohar S; Posch M
    Biom J; 2017 Jul; 59(4):609-625. PubMed ID: 27184938
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bayesian basket trial design with false-discovery rate control.
    Zabor EC; Kane MJ; Roychoudhury S; Nie L; Hobbs BP
    Clin Trials; 2022 Jun; 19(3):297-306. PubMed ID: 35128970
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bayesian sample size calculations for a non-inferiority test of two proportions in clinical trials.
    Daimon T
    Contemp Clin Trials; 2008 Jul; 29(4):507-16. PubMed ID: 18201944
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bayesian methods for the design and interpretation of clinical trials in very rare diseases.
    Hampson LV; Whitehead J; Eleftheriou D; Brogan P
    Stat Med; 2014 Oct; 33(24):4186-201. PubMed ID: 24957522
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparing methods for calculating confidence intervals for vaccine efficacy.
    Ewell M
    Stat Med; 1996 Nov 15-30; 15(21-22):2379-92. PubMed ID: 8931208
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bayesian decision theoretic two-stage design in phase II clinical trials with survival endpoint.
    Zhao L; Taylor JM; Schuetze SM
    Stat Med; 2012 Jul; 31(17):1804-20. PubMed ID: 22359354
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Bayesian approach for incorporating economic factors in sample size design for clinical trials of individual drugs and portfolios of drugs.
    Patel NR; Ankolekar S
    Stat Med; 2007 Nov; 26(27):4976-88. PubMed ID: 17579924
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sample size determination in bioequivalence studies using statistical assurance.
    Ring A; Lang B; Kazaroho C; Labes D; Schall R; Schütz H
    Br J Clin Pharmacol; 2019 Oct; 85(10):2369-2377. PubMed ID: 31276603
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Some thoughts on sample size: a Bayesian-frequentist hybrid approach.
    Gordon Lan KK; Wittes JT
    Clin Trials; 2012 Oct; 9(5):561-9. PubMed ID: 22865839
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Four statistical frameworks for assessing an immune correlate of protection (surrogate endpoint) from a randomized, controlled, vaccine efficacy trial.
    Gilbert PB; Fong Y; Hejazi NS; Kenny A; Huang Y; Carone M; Benkeser D; Follmann D
    Vaccine; 2024 Apr; 42(9):2181-2190. PubMed ID: 38458870
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
    Zhao L; Woodworth G
    Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimal designs for phase II/III drug development programs including methods for discounting of phase II results.
    Erdmann S; Kirchner M; Götte H; Kieser M
    BMC Med Res Methodol; 2020 Oct; 20(1):253. PubMed ID: 33036572
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bayesian decision making in confirmatory early-stage breast cancer trial.
    Gu E; Zhou X; Zhao J
    Contemp Clin Trials; 2021 Mar; 102():106280. PubMed ID: 33484898
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Bayesian hierarchical surrogate outcome model for multiple sclerosis.
    Pozzi L; Schmidli H; Ohlssen DI
    Pharm Stat; 2016 Jul; 15(4):341-8. PubMed ID: 27061897
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints.
    Zhu W; Jin P; Li JX; Zhu FC; Liu P
    Expert Rev Vaccines; 2017 Sep; 16(9):945-949. PubMed ID: 28548626
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bayesian sample sizes for exploratory clinical trials comparing multiple experimental treatments with a control.
    Whitehead J; Cleary F; Turner A
    Stat Med; 2015 May; 34(12):2048-61. PubMed ID: 25765252
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A C++ program to calculate sample sizes for cost-effectiveness trials in a Bayesian framework.
    Sarker SJ; Whitehead A; Khan I
    Comput Methods Programs Biomed; 2013 Jun; 110(3):471-89. PubMed ID: 23399102
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bayesian sample-size determination methods considering both worthwhileness and unpromisingness for exploratory two-arm randomized clinical trials with binary endpoints.
    Kakizume T; Zhang F; Kawasaki Y; Daimon T
    Pharm Stat; 2020 Jan; 19(1):71-83. PubMed ID: 31496045
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bayesian adaptive design for pediatric clinical trials incorporating a community of prior beliefs.
    Wang Y; Travis J; Gajewski B
    BMC Med Res Methodol; 2022 Apr; 22(1):118. PubMed ID: 35448963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.